Huachung University

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Countdown to the Finals of the ASC24 Student Supercomputer Challenge!

Retrieved on: 
Tuesday, April 2, 2024
Research, Apps, Applications, Technology, Oil, Gas, Software, Energy, Hardware, University, Science, Education, Peking University, Shanghai Jiao Tong University, Algorithm, Southwest Petroleum University, Shanghai University, Overalls, Student, LLM, Huachung University, ASC, Water, University of Erlangen–Nuremberg, Lanzhou University, Chinese, National university

The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.

Key Points: 
  • The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.
  • Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students.
  • Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them.
  • The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.

ASC24 Student Supercomputer Challenge: Twenty-five University Teams Worldwide Advance to the Finals

Retrieved on: 
Wednesday, February 7, 2024
Research, Technology, Engineering, Software, Manufacturing, Hardware, University, Data Management, Science, Education, Memory, Southwest Petroleum University, Shanghai University, CPU, Peking University, National university, Chinese, Shanghai Jiao Tong University, National Tsing Hua University, National University of Córdoba, University of Erlangen–Nuremberg, LLM, ASC, Water, Data, Qinghai University, Huachung University, Algorithm, Risk management

Over 300 universities worldwide participated, with twenty-five standout teams advancing to the finals.

Key Points: 
  • Over 300 universities worldwide participated, with twenty-five standout teams advancing to the finals.
  • Among the finalists are renowned institutions such as Huazhong University of Science and Technology, Peking University, the Chinese University of Hong Kong, National Tsing Hua University, Friedrich-Alexander-University Erlangen-Nuremberg, and the National University of Cordoba.
  • The ASC24 finals feature a lineup of traditional powerhouses, including Peking University - the champion of the 10th ASC onsite finals; the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals; University of Science and Technology of China; Shanghai Jiao Tong University; and Friedrich-Alexander-University Erlangen-Nuremberg.
  • Additionally, there is great excitement surrounding the debut of teams from National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, marking their first appearance in the ASC finals this year.

Efabless Unveils Winners of 3rd AI-Generated Open-Source Chip Design Challenge

Retrieved on: 
Tuesday, December 5, 2023
Architecture, Amaranth, School, Documentation, Microsoft, Electricity, Huachung University, Diehard tests, Python, SNN, ChatGPT, PALO, Caravel, Boat, PWM, GDS, HUST, Creativity, RTL

PALO ALTO, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Efabless Corporation, the creator platform for chips, today announced the winners of the third AI Generated Open-Source Silicon Design Challenge.

Key Points: 
  • PALO ALTO, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Efabless Corporation, the creator platform for chips, today announced the winners of the third AI Generated Open-Source Silicon Design Challenge.
  • Equipped with generative AI tools, contestants were invited to showcase their technical skills by crafting a complete Verilog model for their proposed design.
  • The challenge required seamless integration with Efabless' chipIgnite – featuring the Caravel SoC for rapid chip-level development – and OpenLane, the open-source RTL-to-GDS digital design flow.
  • This design utilizes Amaranth, a Python HDL, to create a hardware-based pseudorandom number generator design.

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

Retrieved on: 
Monday, December 11, 2023
Huachung University, Multiple myeloma, Triple, Ophthalmology, HKEX, Safety, SAN, Hope, Treatment, Progression-free survival, ASH, Risk, Tongji Hospital station, Tongji Medical College, Patient, PFS, MRD, Marketing, Trial of the century, Medicine, VCN, Prognosis, Peking Union Medical College, ORR, Cancer, Survival, RRMM, BCMA, Quality of life, Society, Autoimmunity, Pharmaceutical industry, Medical device, Vaccine, Hematology

The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Key Points: 
  • The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.
  • As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients.
  • Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%.
  • Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative.

Embracing the New Horizon, Towards the Shared Future

Retrieved on: 
Friday, December 1, 2023
Petro, Huachung University, APEX, Chinese Academy of Engineering, OMC, Conference, A Shared Future, Organization, EPEC, Information, Commerce, Dance, OT, Education minister, Foodservice, ABB, Friends, CNPC, Sustainable development, ARC, AI, Chinese Academy of Sciences, Economy, Perception, Dahua Technology, New Horizon, ITEI, Information technology, Artificial intelligence, Rockwell Automation, Dancing with the Stars, Exhibition, Speech, Control, Advanced process control, Skin, Device, HSE, Alibaba Group, MAC, SINOPEC, Process, Urbanization, MIIT, PRIDE, East China University, Uncertainty, Digital electronics, Digital, Management, Lenovo, Automation, Engineering

HANGZHOU, China, Dec. 1, 2023 /PRNewswire/ -- November 23rd, SUPCON (688777.SH, SUPCON.SW) held the 30th Anniversary celebration event themed "Embracing the New Horizon, Towards the Shared Future" at the Hangzhou Olympic Sports Center. The event witnessed the gathering of over 6,000 SUPCON group members sharing the joy of three decades of remarkable achievements. More than 100,000 global spectators participated in the online livestream.

Key Points: 
  • HANGZHOU, China, Dec. 1, 2023 /PRNewswire/ -- November 23rd, SUPCON (688777.SH, SUPCON.SW) held the 30th Anniversary celebration event themed "Embracing the New Horizon, Towards the Shared Future" at the Hangzhou Olympic Sports Center.
  • The event witnessed the gathering of over 6,000 SUPCON group members sharing the joy of three decades of remarkable achievements.
  • "Looking ahead, the future is full of uncertainty," he said, "however, I hope SUPCON would make certain to persist in five key aspects: Create value for customers and society.
  • Today, SUPCON stands as a public and global entity, continuously embracing new challenges alongside industrial partners and nearly 30,000 process industry clients.

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Retrieved on: 
Monday, August 21, 2023
Huazhong University of Science and Technology, Bleeding, Hematology, SC, Medicine, New Drug Application, NDA, ITP, Huachung University, Committee, Breakthrough therapy, Tongji Medical College, HKEX, Peking Union Medical College, The Lancet, Patient, Risk, Union Hospital, National Medical Products Administration, Principal, Safety, NMPA, Wuhan Union Hospital, Disease, Bone marrow, Pharmaceutical industry, Nursing, FC, MD

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints in adult patients with primary immune thrombocytopenia (“ITP”) in China. HUTCHMED plans to submit the New Drug Application (“NDA”) around the end of 2023.

Key Points: 
  • The National Medical Products Administration of China (“NMPA”) granted Breakthrough Therapy designation (“BTD”) to sovleplenib for the indication studied in ESLIM-01 in January 2022.
  • As such, the sovleplenib NDA may be considered for priority review for its use in ITP.
  • ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in 188 adult patients with primary ITP who have received at least one prior line of standard therapy.
  • Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (“Syk”) for the treatment of hematological malignancies and immune diseases.

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Phoenix Motorcars Promotes Dr. Frank Lee and Adds Dr. Joseph Xiang to Senior Management Team

Retrieved on: 
Monday, April 24, 2023
Automotive Manufacturing, EV, Electric Vehicles, Automotive, Manufacturing, Trucking, Transport, General Automotive, Alternative Vehicles, Fuels, Logistics, Supply Chain Management, Alternative Energy, Energy, Karma, MSEE, Ohio State University, BS, University, Smart electric drive, MI, Visteon, Engineering, ICE, PEV, PHEV, Ford, Huachung University, EREV, BYD Auto, BSEE, Karma Automotive, Huazhong University of Science and Technology, Geely, Corporation, CFO, Knowledge, Phoenix Motorcars, Management, Electricity, Mechanics

“We are proud to be able to attract such talented, seasoned industry veterans,” said Dr. Lance Zhou, CEO of Phoenix Motorcars.

Key Points: 
  • “We are proud to be able to attract such talented, seasoned industry veterans,” said Dr. Lance Zhou, CEO of Phoenix Motorcars.
  • “The promotion of Frank and the addition of Joseph to our senior management team further positions Phoenix for success as we continue to execute on our global growth strategy.”
    Chris Wang, CFO of Phoenix Motorcars, commented, “The promotion of Frank and addition of Joseph lends additional knowledge and expertise to our operational and technical capabilities.
  • I am proud of the team we have built and our successes to date.
  • Dr. Joseph Xiang brings 35 years of engineering experience, with more than 25 years in the automotive arena.

Collaboratively Developing Transmission, Computing, and Storage Power to Stride Towards the Intelligent World

Retrieved on: 
Sunday, April 23, 2023
Global Analyst Research Settlements, Data-rate units, Huawei, Stride Toward Freedom, Speech, Internet of things, Dean, Data collection, Huachung University, Research, Carbon, Communication, ICT, School, China Unicom, Architecture, Intelligence, Computer science, Mobile phone

SHENZHEN, China, April 23, 2023 /PRNewswire/ -- On April 20th, Huawei held the Striding Towards the Intelligent World Session at Global Analyst Summit 2023.

Key Points: 
  • SHENZHEN, China, April 23, 2023 /PRNewswire/ -- On April 20th, Huawei held the Striding Towards the Intelligent World Session at Global Analyst Summit 2023.
  • Peng Song, Huawei's President of ICT Strategy & Marketing, delivered the keynote speech titled Striding Towards the Intelligent World Through Continuous Innovation.
  • Third, Huawei is building reliable storage facilities to ensure more data can be stored, quickly transmitted, and efficiently used.
  • "Moving forward, we will continue innovating to help customers build leading digital infrastructure, accelerating our journey towards the intelligent world," said Peng.